Angel Sabo
Acute Care · Akron, OHNPI 1699128538
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 334 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by GSK at 24.8% of the total. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 334 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- United Therapeutics Corporation$483
- Boehringer Ingelheim$331
- Amgen$300
- Sanofi$266
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,71697%
- Education$1883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 103 | $1,465 |
| AstraZeneca | 52 | $1,037 |
| United Therapeutics Corporation | 28 | $483 |
| Boehringer Ingelheim | 20 | $331 |
| Amgen | 16 | $300 |
| Sanofi | 14 | $266 |
| Regeneron Healthcare Solutions, Inc. | 12 | $259 |
| Actelion Pharmaceuticals US, Inc. | 10 | $182 |
| Jazz Pharmaceuticals Inc. | 7 | $149 |
| Genentech USA, Inc. | 7 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $116 |
| Merck | 5 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Teva Pharmaceuticals USA, Inc. | 5 | $89 |
| Electromed, Inc. | 4 | $87 |
| Mallinckrodt Hospital Products Inc. | 4 | $80 |
| Pfizer | 4 | $69 |
| Insmed, Inc. | 3 | $66 |
| Bayer | 4 | $62 |
| Mylan Specialty L.p. | 4 | $59 |
| Inspire Medical Systems, Inc. | 2 | $56 |
| Harmony Biosciences LLC | 3 | $55 |
| Philips North America LLC | 3 | $51 |
| Verona Pharma, Inc. | 2 | $48 |
| Sunovion Pharmaceuticals Inc. | 3 | $37 |
| Baxter Healthcare | 2 | $35 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $18 |
| Inogen, Inc. | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $18 |
| Phadia US Inc. | 1 | $15 |
| Covis Pharma GmbH | 1 | $15 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$248
How this compares
$5,904 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 56 | $209,294 |
| Dupixent SyringeDupilumab | 54 | $202,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 167 | $153,797 |
| Fasenra PenBenralizumab | 28 | $150,638 |
| TezspireTezepelumab-Ekko | 28 | $122,908 |
| XolairOmalizumab | 39 | $89,628 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $44,244 |
| Spiriva RespimatTiotropium Bromide | 27 | $18,080 |
| EliquisApixaban | 14 | $12,849 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $11,881 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $10,827 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $10,225 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $5,741 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $4,855 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 158 | $4,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,037 | $184,775110 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $1,465 | $168,856193 claims |
| Boehringer IngelheimSpiriva Respimat | $331 | $18,08027 claims |
| PfizerEliquis | $69 | $12,84914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.
Other acute care in Akron
- Jennifer AnthonyAkron$9K
- Sarah SerbAkron$7K
- Megan BerarducciAkron$4K
- Andrea RobinsonCleveland$149K
- Brittney BrowneMonroe$142K
- Jamie McGuireMiamisburg$86K
- Ileah ReichertColumbus$73K
- Davida PraterBeavercreek$46K
- Dawn FrenchAlliance$40K
- Holly McKibbenColumbus$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.